242 related articles for article (PubMed ID: 12794755)
21. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
[TBL] [Abstract][Full Text] [Related]
23. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
24. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
25. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
26. Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer.
Wang J; Walsh G; Liu DD; Lee JJ; Mao L
Cancer Res; 2006 Sep; 66(17):8361-6. PubMed ID: 16951144
[TBL] [Abstract][Full Text] [Related]
27. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
28. Critical role of deltaDNMT3B4/2 in regulating RASSF1A promoter-specific DNA methylation in non-small cell lung cancer.
Wang SH; Liu NH; Wang J; Bai H; Mao L
Chin Med J (Engl); 2008 Sep; 121(17):1712-21. PubMed ID: 19024105
[TBL] [Abstract][Full Text] [Related]
29. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
Dammann R; Yang G; Pfeifer GP
Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
[TBL] [Abstract][Full Text] [Related]
30. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
Lee SM; Lee WK; Kim DS; Park JY
Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
[TBL] [Abstract][Full Text] [Related]
31. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
[TBL] [Abstract][Full Text] [Related]
32. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
33. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
34. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
35. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.
Li J; Zhang Z; Dai Z; Popkie AP; Plass C; Morrison C; Wang Y; You M
Neoplasia; 2003; 5(4):362-6. PubMed ID: 14511407
[TBL] [Abstract][Full Text] [Related]
36. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
[TBL] [Abstract][Full Text] [Related]
37. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma.
Lo KW; Kwong J; Hui AB; Chan SY; To KF; Chan AS; Chow LS; Teo PM; Johnson PJ; Huang DP
Cancer Res; 2001 May; 61(10):3877-81. PubMed ID: 11358799
[TBL] [Abstract][Full Text] [Related]
38. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma.
Agathanggelou A; Bièche I; Ahmed-Choudhury J; Nicke B; Dammann R; Baksh S; Gao B; Minna JD; Downward J; Maher ER; Latif F
Cancer Res; 2003 Sep; 63(17):5344-51. PubMed ID: 14500366
[TBL] [Abstract][Full Text] [Related]
40. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.
Noda H; Kato Y; Yoshikawa H; Arai M; Togashi K; Nagai H; Konishi F; Miki Y
J Exp Clin Cancer Res; 2006 Jun; 25(2):235-42. PubMed ID: 16918136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
